1. Scrip
  2. >>Business
  3. >>Strategy

BIO 2020 Notebook: Conversations On Rebates, Racism And Remote Working

 
• By Scrip Team

News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.

BIO 2020 Notebook
• Source: Shutterstock

Biopharma efforts to revitalize reform of the US drug rebate system will mobilize again after the November presidential election, policy experts suggested during a panel session on drug pricing at the Biotechnology Innovation Organization’s virtual international convention.

Although the COVID-19 pandemic has sidelined major initiatives in the near term, concerns with high drug prices have not gone away and panelists suggested that various administrative drug pricing actions...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

More from Business

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.